A promising daily tablet is effective at increasing height and improving proportional limb growth in children with achondroplasia, the most common form of dwarfism, according to a new study.

At the core of achondroplasia's pathology lies the hyperactivation of FGFR3, which impairs not only the growth of long bones but also affects cranial, spinal, and vertebral development. The ...

A promising daily tablet is effective at increasing height and improving proportional limb growth in children with achondroplasia, the most common form of dwarfism, according to a new study.

TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly and designed to treat individuals with achondroplasia by providing continuous exposure of ...

TAIPEI (Taiwan News) — The National Health Insurance Administration passed a decision on Friday to include a new treatment for the rare disease achondroplasia, a type of dwarfism, in its coverage. The ...